{"title":"关于结直肠癌患者不同免疫检查点的预后价值和临床病理意义的综合研究：系统回顾与元分析","authors":"Mahdieh Azizi PhD , Zahra Mokhtari MSc , Shirin Tavana MSc , Peyman Bemani PhD , Zahra Heidari PhD , Roghayeh Ghazavi PhD , Marzieh Rezaei PhD","doi":"10.1016/j.curtheres.2024.100760","DOIUrl":null,"url":null,"abstract":"<div><h3>Background</h3><div>The prognostic significance of immune checkpoint expression in the tumor microenvironment has been widely investigated in colorectal cancers. However, the results of these studies are inconsistent and limited to some immune checkpoints.</div></div><div><h3>Objective</h3><div>The study aimed to investigate the correlation between different immune checkpoint expression and clinicopathological features and prognostic parameters.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of the published literature in PubMed, Web of Science-Core Collection, Scopus, Embase, and Cochrane databases to summarize the association between various immune checkpoints expression on both tumor cells and immune cells with clinicopathological features and prognostic parameters in patients with colorectal cancer.</div></div><div><h3>Results</h3><div>One hundred four studies incorporating 22,939 patients were included in our meta-analysis. Our results showed that among the B7 family, the high expression of B7H3, B7H4, PD-1, and PD-L1 on tumor cells and tumor tissue was significantly associated with higher T stage, advanced tumor, node, metastasis (TNM) stage, presence of vascular invasion, and lymphatic invasion. In addition, patients with high expression of B7H3, B7H4, PD-1, PD-L1, and PD-L2 were associated with shorter overall survival. High expression of PD-1 and PD-L1 in immune cells correlated with the absence of lymph node metastasis, lower TNM stage, early T stage, poor overall survival, and disease-free survival, respectively. Moreover, we found significant positive correlations between CD70 and Galectin-3 expression with advanced T stage. HLA-II overexpression was correlated with the absence of lymph node metastasis (odds ratio = 0.21, 95% CI = 0.11–0.38, <em>P</em> < 0.001) and early TNM stage (odds ratio = 0.35, 95% CI = 0.26–0.47, <em>P</em> < 0.001).</div></div><div><h3>Conclusions</h3><div>Overexpression of B7H3, B7H4, PD-1, PD-L1, PD-L2, CD70, and Galectin-3 on tumors is significantly associated with unfavorable clinicopathological characteristics and poor prognostic factors. Hence, these immune checkpoints can serve as predictive biomarkers for prognosis and the clinicopathological features of colorectal cancer because this is essential to identify patients suitable for anticancer therapy with immune checkpoint inhibitors.</div></div>","PeriodicalId":10920,"journal":{"name":"Current Therapeutic Research-clinical and Experimental","volume":"101 ","pages":"Article 100760"},"PeriodicalIF":1.6000,"publicationDate":"2024-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis\",\"authors\":\"Mahdieh Azizi PhD , Zahra Mokhtari MSc , Shirin Tavana MSc , Peyman Bemani PhD , Zahra Heidari PhD , Roghayeh Ghazavi PhD , Marzieh Rezaei PhD\",\"doi\":\"10.1016/j.curtheres.2024.100760\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<div><h3>Background</h3><div>The prognostic significance of immune checkpoint expression in the tumor microenvironment has been widely investigated in colorectal cancers. However, the results of these studies are inconsistent and limited to some immune checkpoints.</div></div><div><h3>Objective</h3><div>The study aimed to investigate the correlation between different immune checkpoint expression and clinicopathological features and prognostic parameters.</div></div><div><h3>Methods</h3><div>We conducted a systematic review and meta-analysis of the published literature in PubMed, Web of Science-Core Collection, Scopus, Embase, and Cochrane databases to summarize the association between various immune checkpoints expression on both tumor cells and immune cells with clinicopathological features and prognostic parameters in patients with colorectal cancer.</div></div><div><h3>Results</h3><div>One hundred four studies incorporating 22,939 patients were included in our meta-analysis. Our results showed that among the B7 family, the high expression of B7H3, B7H4, PD-1, and PD-L1 on tumor cells and tumor tissue was significantly associated with higher T stage, advanced tumor, node, metastasis (TNM) stage, presence of vascular invasion, and lymphatic invasion. In addition, patients with high expression of B7H3, B7H4, PD-1, PD-L1, and PD-L2 were associated with shorter overall survival. High expression of PD-1 and PD-L1 in immune cells correlated with the absence of lymph node metastasis, lower TNM stage, early T stage, poor overall survival, and disease-free survival, respectively. Moreover, we found significant positive correlations between CD70 and Galectin-3 expression with advanced T stage. HLA-II overexpression was correlated with the absence of lymph node metastasis (odds ratio = 0.21, 95% CI = 0.11–0.38, <em>P</em> < 0.001) and early TNM stage (odds ratio = 0.35, 95% CI = 0.26–0.47, <em>P</em> < 0.001).</div></div><div><h3>Conclusions</h3><div>Overexpression of B7H3, B7H4, PD-1, PD-L1, PD-L2, CD70, and Galectin-3 on tumors is significantly associated with unfavorable clinicopathological characteristics and poor prognostic factors. Hence, these immune checkpoints can serve as predictive biomarkers for prognosis and the clinicopathological features of colorectal cancer because this is essential to identify patients suitable for anticancer therapy with immune checkpoint inhibitors.</div></div>\",\"PeriodicalId\":10920,\"journal\":{\"name\":\"Current Therapeutic Research-clinical and Experimental\",\"volume\":\"101 \",\"pages\":\"Article 100760\"},\"PeriodicalIF\":1.6000,\"publicationDate\":\"2024-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Current Therapeutic Research-clinical and Experimental\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://www.sciencedirect.com/science/article/pii/S0011393X24000304\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q3\",\"JCRName\":\"MEDICINE, RESEARCH & EXPERIMENTAL\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Current Therapeutic Research-clinical and Experimental","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0011393X24000304","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0
摘要
背景免疫检查点在肿瘤微环境中的表达对结直肠癌预后的意义已被广泛研究。本研究旨在探讨不同免疫检查点表达与临床病理特征和预后参数之间的相关性。方法我们对PubMed、Web of Science-Core Collection、Scopus、Embase和Cochrane数据库中已发表的文献进行了系统回顾和荟萃分析，总结了结直肠癌患者中肿瘤细胞和免疫细胞上各种免疫检查点的表达与临床病理特征和预后参数的相关性。结果表明，在 B7 家族中，B7H3、B7H4、PD-1 和 PD-L1 在肿瘤细胞和肿瘤组织上的高表达与较高的 T 分期、肿瘤晚期、结节、转移（TNM）分期、血管侵犯和淋巴侵犯显著相关。此外，B7H3、B7H4、PD-1、PD-L1 和 PD-L2 高表达的患者总生存期较短。免疫细胞中PD-1和PD-L1的高表达分别与无淋巴结转移、较低的TNM分期、早期T分期、较差的总生存期和无病生存期相关。此外，我们还发现 CD70 和 Galectin-3 的表达与 T 期晚期呈显著正相关。HLA-II 过表达与无淋巴结转移（几率比 = 0.21，95% CI = 0.11-0.38, P <0.001）和 TNM 早期（几率比 = 0.35，95% CI = 0.26-0.结论肿瘤上 B7H3、B7H4、PD-1、PD-L1、PD-L2、CD70 和 Galectin-3 的过表达与不利的临床病理特征和不良预后因素显著相关。因此，这些免疫检查点可作为结直肠癌预后和临床病理特征的预测性生物标志物，因为这对于确定适合使用免疫检查点抑制剂进行抗癌治疗的患者至关重要。
A Comprehensive Study on the Prognostic Value and Clinicopathological Significance of Different Immune Checkpoints in Patients With Colorectal Cancer: A Systematic Review and Meta-Analysis
Background
The prognostic significance of immune checkpoint expression in the tumor microenvironment has been widely investigated in colorectal cancers. However, the results of these studies are inconsistent and limited to some immune checkpoints.
Objective
The study aimed to investigate the correlation between different immune checkpoint expression and clinicopathological features and prognostic parameters.
Methods
We conducted a systematic review and meta-analysis of the published literature in PubMed, Web of Science-Core Collection, Scopus, Embase, and Cochrane databases to summarize the association between various immune checkpoints expression on both tumor cells and immune cells with clinicopathological features and prognostic parameters in patients with colorectal cancer.
Results
One hundred four studies incorporating 22,939 patients were included in our meta-analysis. Our results showed that among the B7 family, the high expression of B7H3, B7H4, PD-1, and PD-L1 on tumor cells and tumor tissue was significantly associated with higher T stage, advanced tumor, node, metastasis (TNM) stage, presence of vascular invasion, and lymphatic invasion. In addition, patients with high expression of B7H3, B7H4, PD-1, PD-L1, and PD-L2 were associated with shorter overall survival. High expression of PD-1 and PD-L1 in immune cells correlated with the absence of lymph node metastasis, lower TNM stage, early T stage, poor overall survival, and disease-free survival, respectively. Moreover, we found significant positive correlations between CD70 and Galectin-3 expression with advanced T stage. HLA-II overexpression was correlated with the absence of lymph node metastasis (odds ratio = 0.21, 95% CI = 0.11–0.38, P < 0.001) and early TNM stage (odds ratio = 0.35, 95% CI = 0.26–0.47, P < 0.001).
Conclusions
Overexpression of B7H3, B7H4, PD-1, PD-L1, PD-L2, CD70, and Galectin-3 on tumors is significantly associated with unfavorable clinicopathological characteristics and poor prognostic factors. Hence, these immune checkpoints can serve as predictive biomarkers for prognosis and the clinicopathological features of colorectal cancer because this is essential to identify patients suitable for anticancer therapy with immune checkpoint inhibitors.
期刊介绍：
We also encourage the submission of manuscripts presenting preclinical and very preliminary research that may stimulate further investigation of potentially relevant findings, as well as in-depth review articles on specific therapies or disease states, and applied health delivery or pharmacoeconomics.
CTR encourages and supports the submission of manuscripts describing:
• Interventions designed to understand or improve human health, disease treatment or disease prevention;
• Studies that focus on problems that are uncommon in resource-rich countries;
• Research that is "under-published" because of limited access to monetary resources such as English language support and Open Access fees (CTR offers deeply discounted English language editing);
• Republication of articles previously published in non-English journals (eg, evidence-based guidelines) which could be useful if translated into English;
• Preclinical and clinical product development studies that are not pursued for further investigation based upon early phase results.
京公网安备 11010802042870号
京ICP备2023020795号-1
分享
求助内容：
应助结果提醒方式：
扫码关注我们
